A meta‐analysis comparing the efficacy of antidiabetic drugs in type 2 diabetes found that glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors have favorable effects on certain cardiovascular outcomes in patients with increased cardiovascular risk.43, 44. Here, SLC5A2 is linked to type 2 diabetes mellitus.